Factors influencing triacylglycerol synthesis in permeabilized rat hepatocytes.
Rat hepatocytes were treated with Staphylococcus aureus alpha-toxin to permeabilize their plasma membrane for low-molecular-mass compounds. During incubation with 1 mM labelled fatty acid, phosphatidate and, less clearly, lysophosphatidate rapidly reached a steady state, whereas labelled diacylglycerol accumulated to some extent, at least in the absence of exogenous CDP-choline. Esterification and oxidation were linearly related to the fatty acid concentration, and there was no indication for saturation with acyl-CoA. However, when permeabilized cells were incubated with labelled sn-glycerol 3-phosphate and 1 mM unlabelled fatty acid, glycerolipid synthesis and the level of esterification intermediates reached a plateau between 0.25 and 0.50 mumol of the triose phosphate/ml. The synthesis of phosphatidylcholine was dependent on addition of CDP-choline. In presence of the latter, diacylglycerol no longer accumulated and triacylglycerol synthesis was suppressed, although the sum of synthesized diacylglycerol, triacylglycerol and phosphatidylcholine remained constant. This indicates that the same pool of diacylglycerol is shared by choline-phosphotransferase and diacylglycerol acyltransferase and that the relative activity of these enzymes depends on the CDP-choline supply. Comparison of the levels of the esterification intermediates with the activity of the respective steps of the pathway reveals that, at a fixed fatty acid concentration, glycerophosphate acyltransferase determines the esterification rate, whereas lysophosphatidate acyltransferase and, at low CDP-choline levels, diacylglycerol acyltransferase approach saturation at elevated sn-glycerol 3-phosphate concentration. There is, however, no indication for a regulatory role of phosphatidate phosphohydrolase in this system. The significance of these findings for the regulation of triacylglycerol synthesis under conditions in vivo is discussed.
Stals
H K
HK
Katholieke Universiteit Leuven, Belgium.
Mannaerts
G P
GP
Declercq
P E
PE
D019325:3-O-Methylglucose; D000214:Acyl Coenzyme A / Q000378:metabolism; D000818:Animals; D001427:Bacterial Toxins / Q000494:pharmacology; D002463:Cell Membrane Permeability; D003566:Cytidine Diphosphate Choline / Q000494:pharmacology; D004075:Diglycerides / Q000096:biosynthesis; D004951:Esterification; D005227:Fatty Acids / Q000378:metabolism; D005994:Glycerophosphates / Q000378:metabolism; D006460:Hemolysin Proteins; D007700:Kinetics; D008099:Liver / Q000378:metabolism*; D008297:Male; D008757:Methylglucosides / Q000378:metabolism; D008970:Molecular Weight; D010713:Phosphatidylcholines / Q000096:biosynthesis; D051381:Rats; D011919:Rats, Inbred Strains; D013395:Sucrose / Q000378:metabolism; D014280:Triglycerides / Q000096:biosynthesis*
D000214:Acyl Coenzyme A; D001427:Bacterial Toxins; D004075:Diglycerides; D005227:Fatty Acids; D005994:Glycerophosphates; D006460:Hemolysin Proteins; D008757:Methylglucosides; D010713:Phosphatidylcholines; D014280:Triglycerides; C021091:staphylococcal alpha-toxin; D019325:3-O-Methylglucose; D003566:Cytidine Diphosphate Choline; D013395:Sucrose; C029620:alpha-glycerophosphoric acid